Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amisodin Safety and PK in Healthy Adults
NCT07221240Phase 1Recruiting
- Sponsor
- PRG Science & Technology
- Start
- Oct 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Amisodin with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events. Started Oct 2025; status: recruiting.
02
Drugs
amisodin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07221240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221240.